![Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design - Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design -](https://www.thelancet.com/cms/attachment/3c4fe8b1-e2b1-4f4a-9ae1-9ac716671d29/gr2_lrg.jpg)
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design -
![0339 ) MARCO ANTONETTO NORMALINE ERBE 60CPR by ( 0339 ) MARCO ANTONETTO : Amazon.de: Drogerie & Körperpflege 0339 ) MARCO ANTONETTO NORMALINE ERBE 60CPR by ( 0339 ) MARCO ANTONETTO : Amazon.de: Drogerie & Körperpflege](https://m.media-amazon.com/images/I/51weptcKWXL._SR600%2C315_PIWhiteStrip%2CBottomLeft%2C0%2C35_SCLZZZZZZZ_FMpng_BG255%2C255%2C255.jpg)
0339 ) MARCO ANTONETTO NORMALINE ERBE 60CPR by ( 0339 ) MARCO ANTONETTO : Amazon.de: Drogerie & Körperpflege
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer
![Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/f8480e9b-a757-468d-9750-713e4a6ce845/gr1.gif)
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology
![Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/9b4180f6-0d2e-4631-b126-8a4a309031e5/gr2_lrg.jpg)
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Pro
![Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study - European Urology Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study - European Urology](https://www.europeanurology.com/cms/asset/9f70f2ea-c603-4fb4-9959-ca62b8738b90/gr1.jpg)